Third-line treatment of biliary tract cancers in a real-life setting
A. Boilève, A. Mihaele, M. Khoury, A. Hollebecque, C. Smolenschi, L. Antoun, N. Masri, M. Valéry, T. Pudlarz, A. Fuerea, F. Facchinetti, A. Tarabay, D. Malka, V. Boige, M.-L. Tanguy, M. Ducreux · 2026
Read Third-line treatment of biliary tract cancers in a real-life setting by A. Boilève, A. Mihaele, M. Khoury, A. Hollebecque, C. Smolenschi, L. Antoun, N. Masri, M. Valéry, T. Pudlarz, A. Fuerea, F. Facchinetti, A. Tarabay, D. Malka, V. Boige, M.-L. Tanguy, M. Ducreux (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13459572.txt.
Description
A. Boilève and colleagues reviewed in 2026 what happened to patients with biliary tract cancers who reached third-line treatment at a specialized French center. These rare cancers of the bile duct lining are usually found late, and no third-line standard has been proven in randomized trials. The analysis covered 256 patients treated between 2012 and 2023, receiving regimens from targeted drugs to several chemotherapy combinations.
Among patients whose tumors lacked a drug-targetable alteration, median survival on third-line therapy was a little over ten months. Paclitaxel outperformed the FOLFIRI combination, giving median survival of thirteen months against seven months, with slightly longer time before the disease progressed. The authors present paclitaxel as the stronger option here and call for research on which patients benefit most.
Catalog record
| CREATOR | A. Boilève, A. Mihaele, M. Khoury, A. Hollebecque, C. Smolenschi, L. Antoun, N. Masri, M. Valéry, T. Pudlarz, A. Fuerea, F. Facchinetti, A. Tarabay, D. Malka, V. Boige, M.-L. Tanguy, M. Ducreux |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32412 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |